Mitsui Toatsu Chemicals, Incorporated

Yamasa Corporation

Rational Drug Design Laboratories

Polytronics, Ltd.

Shiro Shigeta

Tamotsu Fukuda

Hiroaki Mitsuya

Haruhiko Machida

Hiroshi Ohrui

Satoru Kohgo

Eiichi Kodama

Tadashi Sudo

Yasuyuki Kuroiwa

Hiroaki Okuya

Tomoyuki Yokota

Masanori Baba

Teruhiko Ide

Yasuaki Hanasaki

Hiromitsu Takayama

Kimio Katsuura

Kenji Sudo

Masatoshi Fujiwara

Hisayoshi Ooka

Toshihiro Yamase

Yasuyuki Kuriowa

Yasushi Ono

Ryu Sato

Tsuyoshi Kajiyashiki

Wataru Watanabe

Shin-ichiro Sakai

Katsushi Ijichi

A compound for use especially as an antiviral drug, mainly containing salts of heteropolyanions consisting of a tungstoantimonate (III) vanadium-mixed metal oxide or related salts represented by formula &lsqb;(XW O ) V O &rsqb; , where p is a positive number between 9 and 12 and X is Sb, P. As or Bi and especially Sb. An antiviral drug having a broad spectrum of antiviral activity, high potent efficacy and low toxicity is provided.

Antiviral drugs containing heteropolyanions

4&prime;-C-ethynyl pyrimidine nucleosides and pharmaceutical compositions thereof

The invention provides 4&prime;-C-ethynyl pyrimidine nucleosides (other than 4&prime;-C-ethynylthymidine) represented by formula &lsqb;I&rsqb;:

4&prime;-C-ethynyl pyrimidine nucleoside compounds and pharmaceutical compositions

Arylthiadiazole derivative and antiviral agent containing the same

Antiviral agent containing benzodithiin derivative as active ingredient

The present invention relates to human monoclonal antibodies capable of plurally binding with O-antigens of Pseudomonas aeruginosa, relates to novel parent cell lines for producing human hybridomas derived from human immunoglobulin synthesizing cells, which cell lines themselves incapable of producing human immunoglobulin and capable of fusing with human antibody-producing cells, relates to human-human hybridomas which can secrete monoclonal antibodies capable of binding with at least one of serotypes of Pseudomonas aeruginosa, relates to pharmaceutical compositions for prophylaxis or therapy of Pseudomonas aeruginosa infectious diseases, and relates to prophylactic or therapeutic methods for Pseudomonas aeruginosa infectious diseases.

Transformed cell lines producing human monoclonal antibodies specific

PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudomonas aeruginosa infection.

Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent

PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudonomas aeruginosa infection.

Growing community of inventors

Fukushima, Japan

Shiro Shigeta